



SOCIUM

SOCIUM Inc.

Company  
Representative  
Telephone

Dr. Hiroshi Kawai, CEO  
(0)3-6869-7996

## **Sumitomo Dainippon Pharma to Collaborate with SOCIUM Joint Research Aims to Reveal Neuroprotective Mechanism in Tauopathy**

SOCIUM Inc. (Head office: Chuo-ku, Tokyo, CEO: Dr. Hiroshi Kawai; “Socium”) announced that the company has entered into a joint research agreement with Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Mr. Hiroshi Nomura; “Sumitomo Dainippon Pharma”) for revealing the neuroprotective mechanism in tauopathy.

### **About Joint Research:**

This joint research was triggered by Sumitomo Dainippon Pharma’s open innovation activity “PRISM” in Japan. The goal of this joint research is to reveal the neuroprotective mechanism of Sumitomo Dainippon Pharma’s proprietary compounds which have shown remarkable efficacy in a tauopathy model by using Socium’s unique AI drug discovery platform “Compound-Eyes™, Drug Saver™, and Cyber-Drug-Discovery™”. In addition, the both companies will pursue the possibility of further strategic collaboration through this joint research.

We will combine the cutting-edge technologies of the both companies to discover the therapeutic agent for patients with no drug, drug discovery for patients with ineffective drug in this joint research.

### **About Tauopathy:**

Tauopathy is a general term for neurodegenerative disorders in which abnormal accumulation of intracellular tau protein results in

neurofibrillary changes. Tau protein is a microtubule-binding protein that accumulates intracellularly when it is hyperphosphorylated, released from the microtubules, and becomes fibrotic.

#### **About Sumitomo Dainippon Pharma Co., Ltd.:**

Sumitomo Dainippon Pharma Co., Ltd. defines its corporate mission as to broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide. By channeling our efforts into the research and development of new drugs, Sumitomo Dainippon Pharma aims to realize our mission and provide innovative and effective pharmaceutical solutions not only to people in Japan but also around the world.

For more information, please visit <https://www.ds-pharma.com/>.

#### **About SOCIUM Inc.:**

SOCIUM Inc. is the AI-driven drug discovery company focusing on discovery of first-in-class small molecules. The company is committed to overcoming the unmet medical needs of patients suffering from diseases with the vision of “Drug discovery for patients with no drug, Drug discovery for patients with ineffective drug”. The company identifies novel disease target and mechanism of action by using its unique AI drug discovery platform “Compound-Eyes™, Drug Saver™, and Cyber-Drug-Discovery™”. The company has its own development portfolio which includes projects in oncology and orphan diseases. For more information, please visit <https://socium.co.jp/>

#### **Media Inquiries**

SOCIUM Inc.

AIST Tokyo Waterfront BIO-IT Research Building,  
2-4-7, Aomi, Koto-ku, Tokyo 135-0064, JAPAN

E-mail: [contact@socium.co.jp](mailto:contact@socium.co.jp)

Web: <https://socium.co.jp/>